Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silence Therapeutics ADR Representing 3 Ord Shs SLN

Healthcare Biotechnology
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence... see more

Recent & Breaking News (NDAQ:SLN)

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

Business Wire February 6, 2023

Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

Business Wire January 12, 2023

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2023

Silence Therapeutics Reports Third Quarter 2022 Results

Business Wire November 10, 2022

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire November 9, 2022

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Business Wire November 5, 2022

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Business Wire September 29, 2022

Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

Business Wire September 27, 2022

Silence Therapeutics to Participate in September Investment Conferences

Business Wire September 8, 2022

Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Business Wire September 8, 2022

Silence Therapeutics Announces Pricing of Underwritten Offering

Business Wire August 11, 2022

Silence Therapeutics to Present at Jefferies Healthcare Conference

Business Wire June 2, 2022

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Business Wire May 18, 2022

Silence Therapeutics Reports First Quarter 2022 Results

Business Wire May 16, 2022

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

Business Wire April 25, 2022

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

Business Wire April 6, 2022

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)

Business Wire April 3, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Business Wire April 3, 2022

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

Business Wire March 23, 2022

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Business Wire March 17, 2022